Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of inotuzumab ozogamicin plus rituximab in relapsed/refractory CD22-positive diffuse large B-cell lymphoma eligible for autologous stem cell transplantation
2008-007802-12Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inotuzumab ozogamicin and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Pfizer. Primary endpoint: Overall objective response rate. Started Apr 2009; status: completed.
02
Drugs
inotuzumab ozogamicinrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2008-007802-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007802-12.